Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Indication: Ipilimumab/Nivolumab for Unresectable HCC
Phase 3, open-label, global, randomized trial (CheckMate 9DW) Previously untreated unresectable hepatocellular carcinoma Nivolumab + ipilimumab q3w x4 doses then nivolumab q4w vs.
New Reference: Relatlimab/Nivolumab for Melanoma
Phase 2/3, global, randomized, open-label trial (RELATIVITY-047) Previously untreated, unresectable or metastatic stage III/IV melanoma Nivolumab 480 mg + relatlimab 160 mg q4w vs.
New Reference: Taletrectinib for ROS1+ NSCLC
Pooled, international, open-label, single-arm, phase II studies (TRUST-I and TRUST-II) Advanced or metastatic ROS1+ NSCLC, TKI-naïve or previously treated (crizotinib/entrectinib)
New Reference: Trastuzumab Deruxtecan for her2+ Gastric Cancer
International, randomized, open-label, phase 3 trial (DESTINY-Gastric04) HER2-positive metastatic gastric or GE junction adenoCa after trastuzumab-based therapy Trastuzumab deruxte
New Protocol: Venetoclax with Decitabine for AML Induction in Fit Patients
Phase 2b, multicenter, randomized, open-label, noninferiority trial (NCT05177731) Young (18–59 yrs), newly diagnosed, fit AML patients eligible for intensive chemotherapy Venetoc
New Reference: Vepdegestrant for ER+ Breast Cancer
Phase 3, open-label, randomized trial (VERITAC-2) ER-positive, HER2-negative advanced breast cancer pts previously treated with CDK4/6 inhibitor and endocrine therapy Vepdegestrant
New Protocol: Zanubrutinib with Venetoclax for Untreated CLL
Phase 2, nonrandomized cohort within SEQUOIA trial (SEQUOIA Arm D) Treatment-naïve CLL/SLL patients with or without TP53-aberrant disease Zanubrutinib from cycle 1 + venetoclax ra
New Reference: Zongertinib for her2 Mutated NSCLC
Multicohort, open-label, phase 1a–1b trial (Beamion LUNG-1, NCT04886804) Previously treated advanced or metastatic HER2-mutant NSCLC Zongertinib 120 mg daily (selected dose) in p
New Protocol: TFOX for Advanced Gastric Cancer
Phase 3, open-label, multicenter randomized trial (PRODIGE 51- FFCD-GASTFOX) Pts with previously untreated advanced HER2-negative gastric/GEJ adenocarcinoma TFOX (docetaxel + oxali
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.